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Abstract
Background—While the pentavalent rotavirus vaccine was highly efficacious against rotavirus
diarrhea in clinical trials, the vaccine’s effectiveness under field conditions in the developing
world is unclear. In October, 2006, Nicaragua became the first developing nation to implement
universal infant immunization with the pentavalent rotavirus vaccine. To assess the impact of the
immunization program, we examined the incidence of diarrhea episodes between 2003 and 2009
among children in the state of León, Nicaragua.
Methods—We extracted data on diarrhea episodes from health ministry records. We used scaled
Poisson regression models to estimate diarrhea incidence rate ratios (IRR) for the period following
the program’s implementation to the period before implementation.
Results—Following implementation of the immunization program, diarrhea episodes among
infants were reduced (IRR 0.85, 95% confidence interval [CI] 0.71–1.02) during the rotavirus
season, but appear to have increased during other months.
Conclusions—While the immunization program appears effective in reducing diarrhea episodes
during the rotavirus season, a large burden of diarrhea persists during the remainder of the year.
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INTRODUCTION
Diarrhea is among the leading infectious killers of children worldwide, second only to
pneumonia in its contribution to child mortality. Rotavirus, the most important cause of
diarrhea, is responsible for an estimated 527,000 deaths1 and 138 million episodes of
diarrhea2 in the world each year. While oral rehydration programs have been successful in
reducing the mortality from diarrhea, the overall incidence of diarrhea has not declined since
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the 1950’s.3 The introduction of two rotavirus vaccines in 2006 offered new tools to prevent
both diarrhea episodes and diarrhea-related deaths.
In Nicaragua, rotavirus had been detected in 28% of children who received care for diarrhea.
4 As found elsewhere in the developing world, Nicaraguan children historically acquired
their first rotavirus infection at a young age; by one year, 90% had developed symptomatic
rotavirus diarrhea or had evidence of seroconversion.5 The highest peak of rotavirus
transmission in Central America occurs during the dry season (Quarter 1, January to March).
6
In October, 2006, Nicaragua became the first nation eligible for funding by the GAVI
Alliance to begin universal infant rotavirus immunization. Nicaraguan infants receive the
pentavalent rotavirus vaccine (Rotateq®, Merck) through the national Expanded Program on
Immunization at the ages of 2,4, and 6 months. The rotavirus vaccine was made available to
all infants who were born on or after August, 2006. Children born before this time were not
eligible to receive the vaccine. By the end of 2007, the local health ministry in León,
Nicaragua, reported that the vaccine’s coverage in the state was 98% for receipt of the first
dose, 93% for receipt of the second dose, and 77% for receipt of all three doses. The
coverage for the complete series in León’s 10 municipalities ranged from 61% to 82%.
While the pentavalent rotavirus vaccine was shown to prevent 98% of severe rotavirus
gastroenteritis in clinical trials, these trials occurred primarily in Europe and the United
States.7 It is unclear whether the rotavirus vaccines will perform as well in the developing
world, due to factors such as the distribution of rotavirus genotypes8–11, the simultaneous
use of the oral polio vaccine12–14, a higher prevalence of malnutrition15–17 and
breastfeeding, 18–21 and possible inadequate vaccine storage conditions. The monovalent
rotavirus vaccine provided only 49% efficacy against severe rotavirus gastroenteritis in a
recent clinical trial in Malawi, significantly lower than the vaccine's efficacy in upper-
income countries.22,23 Similarly, a case-control study based in four Nicaraguan hospitals
found the pentavalent rotavirus vaccine to be 58% effective against severe rotavirus
diarrhea.24
To quantify the impact of the rotavirus immunization program in Nicaragua, we compared
the incidence of all-cause diarrhea and diarrhea-related mortality in children before and after
the immunization program using data collected by the local health ministry in the state of
León, Sistemas Locales de Atención Integral a la Salud (SILAIS). By examining the impact
over several years after the introduction of the immunization program, we reduced the effect
of possible annual variation of rotavirus transmission.
METHODS
Setting
The state of León includes Nicaragua’s second largest city, the municipality of León, and
nine rural municipalities. The state’s total estimated population (2009) is 393,340 including
39,562 children under age 5. The climate is tropical with a dry season lasting from
December to April.
Health Facilities and Information Management
The public health care system in León is organized into primary care (13 primary care
centers and 93 health posts) and secondary care (referral hospital in León municipality). All
primary care facilities provide outpatient care for diarrhea, primarily with oral rehydration
solution; the 13 primary care centers are able to initiate intravenous hydration. Children
requiring inpatient care are referred to the hospital. Beginning in 2008, León transitioned to
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sectorización, a model of health care where primary care providers are responsible for a
geographic area. Providers visit families in the area at least annually, and visit young
children more frequently.
All health facilities in Nicaragua are under a government mandate to report all visits for
acute diarrhea episodes and deaths due to diarrhea to their local health ministry. Diarrhea
was defined as ≥ 3 liquid or loose stools within a 24 hour period, with or without
dehydration. Reports are made by "health statisticians" at the primary care centers and
hospital and by nurses at the smaller health posts.
In León, the electronic reportable illnesses database is maintained at the SILAIS office, and
includes information on the patient's age, sex, municipality, and date of the visit to the health
facility. SILAIS estimates that 5% of diarrhea visits are not reported due to limited reporting
from private clinics. Based on hospital records from 2008 and 2009, less than one quarter of
the total diarrhea visits among infants occurred in the hospital setting.
The national census in Nicaragua is conducted every 10 years by the Nicaraguan Institute of
Development Information (INIDE), including in 1995 and 2005. Official regional
population estimates are made by SILAIS for the years between the census; these estimates
incorporate yearly population reports obtained from each health sector, a unit of
approximately 2,000 individuals. According to these estimates, between 2005 and 2009
there was a 1% increase in the total population in the state of León and a 16% decrease in
the size of the under five year old population. The decrease in the childhood population size
in León is attributed to the dramatic decline in the fertility rate among Nicaraguan women,25
and the emigration of Nicaraguan families to neighboring countries in search of economic
opportunities.26
Age categories in the census and reportable illnesses database include “under 12 months”
and “12 to 59 months”. Beginning in August, 2007, all of the children in the "under 12
months" age category would have been eligible to receive the rotavirus vaccine. An
increasing proportion of children in the "12 to 59 month" age category would have been
eligible to receive the vaccine with increasing time since the vaccine's introduction.
Statistical Analyses
The primary outcome examined was the incidence rate of diarrhea episodes among infants in
the pre-vaccine and post-vaccine periods, since infants are the age group with the highest
burden of rotavirus diarrhea, and because older children were not eligible to receive the
vaccine when the program began. We first extracted and plotted the numbers of diarrhea
episodes per week from SILAIS records between January 2003 and September 2009. We
anticipated that vaccine effects would be greatest during the rotavirus season (Quarter 1,
January to March) and defined quarters of interest (weeks 1–13, 14–26, 27–39, 40–52) prior
to data analysis. We grouped the counts of diarrhea episodes by quarter for each year and
municipality. The corresponding exposure time for the infants was estimated as the number
of weeks for which records were available times the number of infants living in the
municipality during the year, based on annual SILAIS population estimates.
We used scaled Poisson regression models to estimate incidence rates of diarrhea episodes
and their corresponding 95% confidence intervals (CI) by quarter. Scaled Poisson regression
analysis was also used to estimate the incidence rate ratio (IRR) and 95% CI among infants
for the period following implementation to the period before implementation, controlling for
municipality, and to examine possible interaction between vaccine period and quarter. We
excluded records for the period of October 16, 2006 to August 15, 2007 in estimating the
IRR, because the program was being rolled out during this time, and not all infants in the
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"under 12 months" age category had the opportunity to receive the vaccine. We planned to
report estimates of the IRRs separately for each quarter if we observed a significant quarter
by vaccine period effect at the alpha=0.10 level. Secondarily, we used the same approach to
estimate the IRR for children aged 12 to 59 months.
We also extracted the numbers of diarrhea-related deaths among children between January
2003 and December 2009. We calculated the rate of diarrhea-related deaths and
corresponding 95% CIs for the pre-vaccine period (January 2003 through December 2006)
and the post-vaccine period (January 2007 through September, 2009). Due to the anticipated
small numbers of diarrhea-related deaths overall, we included all children under age 60
months in the calculation of rates.
RESULTS
Diarrhea Episodes
The numbers of diarrhea episodes by year and surveillance week for both infants and
children are shown in Figure 1. In the period prior to the program’s implementation (January
2003 to October 2006) there were 10,313 diarrhea episodes reported for children under 12
months in the state of León within a total of 38,857 infant years of exposure. In the post-
vaccine period (August 2007 to September 2009) there were 5,280 diarrhea episodes
reported in the same age group, with 17,734 total infant years of exposure. Using yearly
population estimates for each year of the study, the incidence rates by quarter ranged from
15.9 to 31.9 diarrhea episodes per 100 infant years prior to the immunization program. In the
period following program implementation, the incidence rates ranged from 18.7 to 37.5
diarrhea episodes per 100 infant years (Table 1). Incidence rates by quarter for each
individual year are shown in Figure 2.
The IRRs for the periods following versus before the program’s implementation (Table 1)
varied significantly by quarter (P=0.001). In Quarter 1, there was a reduction in the
incidence rate that approached statistical significance (IRR=0.85, 95% CI 0.71–1.02).
However, during Quarters 2 and 3, the incidence rates were higher in the period following
UIRI implementation (Table 1).
Among the children aged 12 to 59 months, the incidence rates by quarter ranged from 6.2 to
11.7 diarrhea episodes per 100 child years before the immunization program and 7.4 to 16.4
diarrhea episodes per 100 child years following the program’s implementation. During
Quarter 1, the incidence rate was unchanged in the period following versus before the
program's implementation (IRR=1.10, 95% CI 0.90–1.34). During the other quarters, the
incidence rates were increased following implementation of the program (Quarter 2:
IRR=1.26, 95% CI 1.06–1.51, Quarter 3: IRR=1.59, 95% CI 1.35–1.87, Quarter 4: 1.21,
95% CI 0.94–1.55).
Since the population estimates showed a considerable decrease in the childhood population
during the years of the study, we performed a sensitivity analysis using the midpoint year
population estimate (2006) for all study years. The IRRs among infants for the periods
before versus following program implementation again varied significantly by quarter
(P=0.001). For Quarter 1, the reduction in the incidence rate among infants was greater
(IRR=0.69, 95% CI 0.58–0.83) than in our primary analysis. During the other quarters, there
were no changes in incidence rates among infants in the period following versus before the
program's implementation (see Table, Supplemental Digital Content 1).
SDC 1: Sensitivity Analysis: Diarrhea Episodes in Infants in the Pre- and Post-Vaccine Periods Using 2006 Population Estimates
[table Supplemental Digital Content 1, http://links.lww.com/INF/A605)
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Deaths from diarrhea for infants and children are shown in Table 2. There were no deaths
among children ages 12 to 59 months in the years following the implementation of the
immunization program. Overall, there were 1.03 diarrhea-related deaths per 10,000 child
years (95% CI 0.64–1.57) in the years prior to the immunization program and 0.82 diarrhea-
related deaths per 10,000 child years (95% CI 0.38–1.56) in the years following the
immunization program’s implementation.
DISCUSSION
In our primary analysis, we found a 15% decrease in all-cause diarrhea incidence among
infants during the rotavirus seasons following the implementation of the immunization
program. During the remainder of the year, we found an unexpected increase in the diarrhea
incidence after implementation of the immunization program. Because population estimates
showed a decrease in the childhood population over the years of the study, we performed a
sensitivity analysis applying the 2006 population estimates for all years of the study. This
analysis revealed a more dramatic decrease in diarrhea incidence of 31% during the
rotavirus seasons following the immunization program, with no changes during the
remainder of the year. These estimates correspond well to the rotavirus prevalence of 28%
among Nicaraguan children with diarrhea prior to the immunization program4, and an
analysis during the first rotavirus season after the immunization program was implemented,
showing a 23% decrease in all-cause diarrhea episodes among infants.27 As the majority of
diarrhea visits occurred to primary care facilities, the modest reduction may reflect the lower
prevalence of rotavirus infection among milder cases of diarrhea as compared to more
severe cases requiring a hospital visit.
Childhood deaths due to diarrhea trended downward in the years following the
immunization program from a rate of 1.03 per 10,000 child years to 0.82 per 10,000 child
years, however, due to the small numbers of deaths overall, we were unable to perform a
rigorous analysis of the effect of the immunization program on diarrhea-related deaths.
Interestingly, there were no reported diarrhea-related deaths among children ages 12 to 59
months in the years following implementation of the immunization program, despite the fact
that a large proportion of children in this age category were not eligible to receive the
vaccine when the program was implemented. This finding suggests either a direct effect of
the vaccine among children over age 12 months in the second and third years of the
immunization program or indirect effects of the vaccine in preventing rotavirus-related
deaths among unimmunized children.
While our results show a reduction in diarrhea incidence during the rotavirus seasons
following the implementation of the immunization program, we did not anticipate a possible
increase in diarrhea incidence during the remainder of the year. As we could not identify a
biologically plausible explanation for an increase in diarrhea episodes, we believe that the
changes in the post-vaccine period may be due to an increase in reporting of diarrhea
episodes. We identified several factors that may be contributing to a change in the reporting
of diarrhea episodes during the post-vaccine period as compared to the pre-vaccine period,
which may bias against the benefit of the vaccine: 1) a health worker strike during late 2005
and early 2006 may have resulted in a decrease in reporting during these months in the pre-
vaccine period, 2) increasing cell phone use in recent years has facilitated collection of
epidemiological data, with less missing reports, 3) sectorización, or placing primary care
providers in the community outside of health facilities beginning in 2008 may have
increased reporting of diarrhea episodes through increased contact between the population
and providers, and, 4) the public awareness campaign during the vaccine's introduction in
2006 may have spurred more parents to bring their children to health providers for diarrhea,
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causing an increase in diarrhea visits. Establishing an active surveillance system for diarrhea
episodes and diarrhea-related deaths in the years prior to the implementation of the
immunization program and ensuring a consistent method of reporting during the years
following the immunization program would have been one way to avoid possible changes in
reporting. However, providing active surveillance at 107 health facilities over a 7 year
period would have required overcoming multiple logistical challenges and great expense.
A potential limitation of the study is our definition of the rotavirus season as the first quarter
of the year, based on regional seasonality data6. We acknowledge that the timing of the
rotavirus season cannot be precisely determined from the available data and may vary from
year to year.
In conclusion, in the years following the introduction of a universal rotavirus immunization
program, there was a reduction in all-cause diarrhea incidence during the rotavirus seasons.
The persistent burden of diarrhea during the remainder of the year draws attention to other
diarrhea etiologies in the post-vaccine period, such as Shigella spp, and enterotoxigenic E.
coli.28 Hygiene, water, and sanitation programs29 or the development of other enteric
vaccines should be pursued in addition to rotavirus immunization programs in order to
reduce childhood diarrhea year-round.
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Numbers of Diarrhea Episodes by Week, 2003 to 2009
Arrow indicates the start date for the rotavirus immunization program.
*Represents the median number of diarrhea episodes among infants by calendar week in the
pre-vaccine period.
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Incidence Rates of Diarrhea Episodes in Infants by Quarter, 2003 to 2009
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Table 1
Diarrhea Episodes in Infants in the Pre- and Post-Vaccine Periods*
Quarter





1 28.7( 24.6–33.4) 24.4 (19.5–30.5) 0.85 (0.71–1.02)
2 31.9 (26.9–37.8) 37.1 (32.7–42.0) 1.16 (1.00–1.35)
3 27.9 (22.2–35.1) 37.5 (33.3–42.2) 1.34 (1.16–1.55)
4 15.9 (13.7–18.3) 18.7 (16.0–21.9) 1.18 (0.95–1.47)
*
Pre-Vaccine, January, 2003 to October, 2006, Post-Vaccine, August, 2007 to September, 2009
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